https://doi.org/10.4081/hmr.v1i4.238

Current treatment indications for von Willebrand factor concentrate

Vol. 1 No. 4: Nordic von Willebrand Workshop 2004
Published: May 29, 2009
Abstract Views: 182
PDF: 459
Untitled (): 0
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Erik Berntorp
support@pagepress.org
Transfusion with blood products containing factor VIII/VWF complex is the treatment of choice for those patients (approx. 20%) who are unresponsive to DDAVP. In developed countries, virucidally treated concentrates of FVIII/VWF complex are today the mainstay of replacement therapy in von Willebrand’s disease (VWD). The treatment indication for von Willebrand factor (VWF) concentrate in an individual patient has to be judged in the light of the severity of the disease and the type of hemostatic challenge. DDAVP can be used in many cases in connection with e.g. minor surgery, whereas concentrate should be used in major surgery. Recent data shows that the rate of biologic response to DDAVP is relatively low, not only in type 2 but also in type 1 VWD (about 1/3), when uniform and stringent criteria for patient selection and responsiveness are applied.1

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Berntorp, E. (2009). Current treatment indications for von Willebrand factor concentrate. Hematology Meeting Reports (formerly Haematologica Reports), 1(4). https://doi.org/10.4081/hmr.v1i4.238
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).